Trial Information

Summary: Moderate to Severe Persistent Asthma

The purpose of study is to assess the effectiveness of Xolair (omalizumab; formerly called olizumab) in people with asthma who still have symptoms despite treatment with AdvairŪ 500/50 twice daily.

You may qualify for this study if you:

  • Are between the ages of 12 and 75
  • Have a history of moderate to severe asthma

You will not qualify for this study if you:

  • Are pregnant and/or breast feeding a child
  • Have an active lung disease other than asthma
  • Have a history of drug or alcohol abuse

Contact:

Alba Raghnauth, Study Coordinator
Biomedical Research Alliance of New York
Montefiore Medical Center
1515 Blondell Avenue
Suite 220
Bronx, NY 10461
Telephone: 718-405-8075
Email:

Profile Page: Biomedical Research Alliance of New York, Bronx, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:50 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA